Massachusetts General Hospital
An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.
Inclusion criteria, participants with AVP-D: * AVP-D diagnosis * Age 7 to 21 years * Stable pituitary hormone replacement (no change in dose of hormone replacement in 4 weeks prior to baseline) * If on estrogen/progestin, participants agree to stop for at least 6 weeks prior to Main study visits * English language proficiency Inclusion criteria, PD: * Pituitary disease diagnosis * Age 7 to 21 years * Eligible participants are not required to be on hormone replacement for pituitary deficiencies. If receiving pituitary hormone replacement, no change in dose in 4 weeks prior to baseline) * If…
Norethindrone Acetate-Ethinyl Estradiol will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and control cohort.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.